AXIM Biotechnologies, Inc.

Equities

AXIM

US05463V1008

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:44:08 30/05/2024 BST			5-day change	1st Jan Change
0.009 ^USD	0.00%		-18.18%	-52.63%

04-16	AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-15	AXIM Biotechnologies, Inc. announced that it has received $0.814555 million in funding	CI

AXIM Biotechnologies, Inc. Appoints Robert Malasek as Chief Financial Officer and Secretary

August 22, 2016 at 11:03 am

On June 29, 2016, AXIM Biotechnologies, Inc. appointed Robert Malasek as the company's Chief Financial Officer and Secretary. Mr. Malasek's experience includes serving as the Assistant Controller for Starwood Hotel & Resorts Worldwide, Inc., Controller for Pacific Crest Equity Partners and Chief Financial Officer for NatureWell, Inc. From 2011 to 2015, Robert served as the Chief Financial Officer, Secretary, Treasurer and a Director of Liberty Coal Energy Corp.

Latest news about AXIM Biotechnologies, Inc.

AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-16	CI
AXIM Biotechnologies, Inc. announced that it has received $0.814555 million in funding	03-14	CI
AXIM Biotechnologies, Inc Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation	02-20	CI
AXIM Biotechnologies, Inc. announced that it expects to receive $0.75 million in funding from Medical Marijuana, Inc.	12-25	CI
AXIM Biotechnologies, Inc. Partners With Auer Precision to Scale Assay Production	12-20	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20	CI
AXIM Biotechnologies Develops First Non-Invasive, Rapid, Point-Of-Care, Diagnostic Test for Parkinson's Disease	12/09/23	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/08/23	CI
AXIM Biotechnologies, Inc. Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test	01/08/23	CI
AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide	12/07/23	CI
AXIM Biotechnologies, Inc. announced that it has received $20 million in funding	31/05/23	CI
AXIM Biotechnologies, Inc. Appoints Kurt Phinney as Chief Operating Officer	23/05/23	CI
AXIM Biotechnologies, Inc. announced that it has received $0.575 million in funding	22/05/23	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	22/05/23	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/04/23	CI
AXIM Biotechnologies, Inc. Auditor Raises 'Going Concern' Doubt	16/04/23	CI
AXIM Biotechnologies, Inc. Files Patent on Fentanyl Neutralizing Antibody Test, Applies for Drug Enforcement Administration License to Work with Controlled Substance	17/01/23	CI
AXIM Biotechnologies, Inc. Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test and Files Provisional Patent	13/12/22	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
AXIM Biotechnologies, Inc. Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch	04/10/22	CI
Axim® Biotechnologies Signs Exclusive Global Commercialization Agreement with Verséa™ Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions	19/09/22	CI
Insider Buy: Axim Biotechnologies	31/08/22	MT
AXIM Biotechnologies, Inc. announced that it has received $0.1 million in funding	28/08/22	CI
AXIM Biotechnologies, Inc. announced that it expects to receive $0.1 million in funding	23/08/22	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/08/22	CI

Chart AXIM Biotechnologies, Inc.

Duration

Period

More charts

Company Profile

Axim Biotechnologies, Inc. is a vertically integrated research and development company. The Company is focused on improving the landscape for the diagnosis of ophthalmological conditions such as dry eye disease (DED) through rapid diagnostic tests. Its core competencies include development of rapid lateral flow immunoassays, reagents, and monoclonal antibody development for such assays. Its product categories include Eye Health, wherein the Company acquired two FDA cleared tests for dye eye disease and has internally developed a third assay; and SARS-CoV-2 neutralizing antibody tests. The Company is focused on developing a proprietary diagnostic platform that can be adapted to test for a variety of analytes including SARS-Cov-2, Lactoferrin, IgE, Lacritin, and MMP-9. Its platform capability can also be applied to rapid testing for vaccine candidates. Its platform can also be used to enable point-of-care detection for one or more cancers using a unique cancer biomarker, QSOX1-L.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AXIM BIOTECHNOLOGIES, INC.	-52.63%	2.62M
MODERNA, INC.	+52.36%	56.69B
IQVIA HOLDINGS INC.	-3.86%	41B
LONZA GROUP AG	+38.14%	38.11B
CELLTRION, INC.	-12.01%	26.89B
ICON PUBLIC LIMITED COMPANY	+14.13%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-21.62%	18.59B
BIO-TECHNE CORPORATION	+0.21%	12.39B
MEDPACE HOLDINGS, INC.	+25.96%	11.99B
UNITED THERAPEUTICS CORPORATION	+23.02%	11.88B

Other Biotechnology & Medical Research